Goldman says stocks like Nvidia have more room to run

Goldman Sachs reiterated a bullish setup on several stocks, highlighting BrightSpring Health Services, Samsara, Ulta Beauty, Nvidia and Johnson & Johnson as buy-rated names with attractive upside. BrightSpring was initiated at Buy with a $71 target, while Ulta kept a $652 target despite a 23% YTD decline and raised guidance; Goldman also cited improving margins at Samsara, stronger capital allocation at Nvidia and a strengthened pharma franchise at J&J. The note is supportive for the individual stocks but is primarily analyst commentary rather than a broad market catalyst.

Analysis

The common thread here is not simply “quality at a premium,” but a market regime shift toward businesses with either pricing power or operational indispensability. IOT and NVDA are the cleanest expressions of that theme: both convert industry standardization into switching costs, which should let them compound even if macro growth slows. BTSGU is more nuanced—its upside is less about the headline growth rate and more about a secular re-rating if investors accept that healthcare delivery fragmentation is a source of durable margin expansion rather than a temporary dislocation.

Second-order effects matter. If Samsara keeps winning share, legacy fleet telematics, industrial software point-solutions, and lower-end hardware vendors will feel pressure on churn and wallet share; that tends to show up first in slower new-logo wins, then in tougher renewal pricing 2-4 quarters later. For BrightSpring, the real beneficiary may be upstream and downstream partners in specialty pharmacy, infusion logistics, and managed care, because scale and care-path integration become the new moat; smaller regional providers are the likely losers as reimbursement complexity rises.

The more interesting contradiction is that the market may still be underestimating how much of this is a duration trade, not a pure earnings trade. NVDA and IOT can rerate on confidence in 2027+ cash flow visibility even if current-quarter beats are modest, while ULTA and JNJ are more about recession-resistant compounding and capital return support. That creates a barbell: expensive growth can keep working if rates fall or stay stable, and defensives can outperform if macro data deteriorates.

The main risk is crowding. These are all consensus-friendly buys, so the near-term vulnerability is not fundamental collapse but multiple compression if the broader market rotates away from quality growth or if any one of these names disappoints on guidance cadence. For ULTA, the downside is that market-share gains can be slower to monetize than investors expect; for JNJ, the risk is that the market already gives credit for the pharma franchise turnaround before the cash flow actually inflects.

Key Decisions for Investors

• Long IOT on any 3-5% pullback over the next 2-3 weeks; target a 12-month hold. Risk/reward favors upside as operating leverage and investor day-type catalysts can expand the multiple even if revenue growth normalizes.
• Add NVDA only on post-event weakness or market-wide selloffs; use a 6-9 month horizon. The risk/reward is asymmetric if 2027 estimates continue to move up faster than the stock de-risks, but avoid chasing into strength given elevated crowding.
• Initiate a pair: long IOT / short a basket of lower-quality industrial software and telematics vendors over 3-6 months. Thesis: standardization and platform consolidation should widen the gap in retention and cross-sell, creating a winner-take-more dynamic.
• Buy BTSGU as a small-cap growth satellite, but size modestly and treat it as a 9-12 month re-rating story. Best entry is after any post-initiation consolidation; the main risk is that the market keeps assigning a conventional healthcare multiple instead of a growth premium.
• Hold ULTA only if you can tolerate near-term multiple volatility; best expressed as a tactical long into any selloff tied to cosmetic-category fears. Upside comes from share gains and buybacks, but thesis breaks if comps decelerate for two consecutive quarters.